Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A comparative retrospective study
Authors
Keywords
-
Journal
HEPATOLOGY RESEARCH
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-06-14
DOI
10.1111/hepr.13801
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Lenvatinib Therapy for Unresectable Hepatocellular Carcinoma in a Real-World Practice in Korea
- (2021) Myung Ji Goh et al. Liver Cancer
- Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study
- (2021) Shigeo Shimose et al. Cancers
- Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update
- (2021) Masatoshi Kudo et al. Liver Cancer
- Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first‐line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study
- (2021) Xiaoyan Ding et al. CANCER
- Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
- (2021) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
- (2021) Biao Yang et al. Frontiers in Oncology
- Role of locoregional therapies in the wake of systemic therapy
- (2020) Daniel H. Palmer et al. JOURNAL OF HEPATOLOGY
- mRECIST for HCC: Performance and novel refinements
- (2020) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma
- (2020) Takeshi Terashima et al. HEPATOLOGY RESEARCH
- Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
- (2020) Xuefeng Kan et al. Frontiers in Oncology
- Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib
- (2020) Tao Sun et al. Frontiers in Molecular Biosciences
- Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR–MAPK cascades
- (2019) Taisuke Hoshi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
- (2018) Masahiro Matsuki et al. Cancer Medicine
- Transarterial chemoembolization: Modalities, indication, and patient selection
- (2015) Wolfgang Sieghart et al. JOURNAL OF HEPATOLOGY
- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now